AVDL,Avadel Pharmaceuticals plc | Healthcare

Healthcare

AVDL

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Avadel Pharmaceuticals plcAVDL

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

Market Cap

708.29M

Revenue (ttm)

169.12M

Net Income (ttm)

-48.83M

Shares Out

96.63M

EPS (ttm)

-0.51

PE Ratio

n/a

Forward PE

46.40

Dividend

n/a

Ex-Dividend Date

n/a

Volume

208,629

Open

7.11

Previous Close

7.13

Day's Range

7.01 - 7.34

52-Week Range

6.38 - 19.09

Beta

1.63

Analysts

Strong Buy

Price Target

18.86 (+157.3%)

Earnings Date

May 7, 2025

Description >

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.

Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy.

The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Latest News >

Energy Capital Partners to acquire Atlantica for $2.56 bln

May 28, 2024

May 28 (Reuters) - Private equity firm Energy Capital Partners will buy Atlantica Sustainable Infrastructure ( AY ) for $2.56 billion in cash, the utility said on Tuesday, in a deal that will give its biggest shareholder funds to lower its debt. Atlantica, which started a strategic review in February last year, will get $22 per share, a near 19%...

--PayPal Planning to Build Ad Business, The Wall Street Journal Reports

May 28, 2024

07:34 AM EDT, 05/28/2024 (MT Newswires) -- Price: 62.42, Change: +0.78, Percent Change: +1.27 ...

Baozun Beats Revenue Estimates with Strong Q1 Growth, Shares Surge

May 28, 2024

Baozun Inc ( BZUN ) reported a fiscal first-quarter 2024 revenue growth of 4.9% year-on-year to 1.98 billion Chinese yuan ($274.2 million), beating the analyst consensus estimate of $269.6 million. Adjusted loss per ADS was $0.03, compared to the analyst consensus estimate of $0.00. The stock price gained after the results. The increase in total net revenues was mainly due to higher product sales...

Merck Says Phase 3 Trial of Keytruda in Triple Negative Breast Cancer Met Overall Survival Endpoint

May 28, 2024

07:34 AM EDT, 05/28/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday that a phase 3 trial evaluating Keytruda in combination with chemotherapy as a treatment for patients with high-risk early-stage triple-negative breast cancer met its overall survival endpoint. The trial evaluated the combination therapy as a pre-operative treatment and as a single agent after surgery, Merck ( MRK...